Pluristyx
Biotechnology, 454 N 34th St, Seattle, Washington, 98103, United States, 11-50 Employees
Who is PLURISTYX
Pluristyx is a pioneering company at the forefront of stem cell technologies. With a mission to revolutionize the field of regenerative medicine, Pluristyx develops innovative solutions t...
Read More
-
Headquarters: 454 N 34th St, Seattle, Washington, 98103, United States
-
Date Founded: 2018
-
Employees: 11-50
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
-
CEO:
Benjamin Fryer
Email
Phone
Industry: Biotechnology
SIC Code: 8641
|
NAICS Code: 54 |
Show More
Pluristyx Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Pluristyx
Answer: Pluristyx's headquarters are located at 454 N 34th St, Seattle, Washington, 98103, United States
Answer: Pluristyx's official website is https://pluristyx.com
Answer: Pluristyx's revenue is $1 Million to $5 Million
Answer: Pluristyx's SIC: 8641
Answer: Pluristyx's NAICS: 54
Answer: Pluristyx has 11-50 employees
Answer: Pluristyx is in Biotechnology
Answer: Pluristyx contact info: Phone number: Website: https://pluristyx.com
Answer: Pluristyx is a pioneering company at the forefront of stem cell technologies. With a mission to revolutionize the field of regenerative medicine, Pluristyx develops innovative solutions that empower breakthroughs in stem cell therapies. The company's proprietary platform, panCELLa, represents a transformative leap in stem cell research, offering enhanced freedom to operate and unparalleled potential for medical advancements at a significantly accelerated timeline. Operating from two cutting-edge North American sites, Pluristyx is dedicated to driving progress and innovation in the realm of stem cell therapies. In July of 2023 Pluristyx and panCELLa merged. Pluristyx offers a portfolio of iPSC-based products and services to provide end-to-end client support in early product development, while panCELLa offers an array of unique and effective technologies with particular strength in gene editing. As one company, Pluristyx and panCELLa offer an enlarged portfolio whose long-term focus is to become the global leader in clinical-grade, genetically modified, off-the-shelf iPSCs with the lowest barrier to entry for cell therapy development, providing clients with the fastest speed to clinic and the best route to commercialization.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month